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Abstract
Background: In the Addona et al. paper (Nature Biotechnology 2009), a large-scale multi-site study was performed to
quantify Multiple Reaction Monitoring (MRM) measurements of proteins spiked in human plasma. The unlabeled signature
peptides derived from the seven target proteins were measured at nine different concentration levels, and their isotopic
counterparts were served as the internal standards.
Methodology/Principal Findings: In this paper, the sources of variation are analyzed by decomposing the variance into
parts attributable to specific experimental factors: technical replicates, sites, peptides, transitions within each peptide, and
higher-order interaction terms based on carefully built mixed effects models. The factors of peptides and transitions are
shown to be major contributors to the variance of the measurements considering heavy (isotopic) peptides alone. For the
light (
12C) peptides alone, in addition to these factors, the factor of study*peptide also contributes significantly to the
variance of the measurements. Heterogeneous peptide component models as well as influence analysis identify the outlier
peptides in the study, which are then excluded from the analysis. Using a log-log scale transformation and subtracting the
heavy/isotopic peptide [internal standard] measurement from the peptide measurements (i.e., taking the logarithm of the
peak area ratio in the original scale establishes that), the MRM measurements are overall consistent across laboratories
following the same standard operating procedures, and the variance components related to sites, transitions and higher-
order interaction terms involving sites have greatly reduced impact. Thus the heavy peptides have been effective in
reducing apparent inter-site variability. In addition, the estimates of intercepts and slopes of the calibration curves are
calculated for the sub-studies.
Conclusions/Significance: The MRM measurements are overall consistent across laboratories following the same standard
operating procedures, and heavy peptides can be used as an effective internal standard for reducing apparent inter-site
variability. Mixed effects modeling is a valuable tool in mass spectrometry-based proteomics research.
Citation: Xia JQ, Sedransk N, Feng X (2011) Variance Component Analysis of a Multi-Site Study for the Reproducibility of Multiple Reaction Monitoring
Measurements of Peptides in Human Plasma. PLoS ONE 6(1): e14590. doi:10.1371/journal.pone.0014590
Editor: Pedro Antonio Valdes-Sosa, Cuban Neuroscience Center, Cuba
Received June 22, 2010; Accepted December 17, 2010; Published January 26, 2011
Copyright:  2011 Xia et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study is supported by a subcontract (29XS081) from the National Cancer Institute. The funder had no role in study design, data analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xq8@niss.org
Introduction
Mass spectrometry-based proteomics has emerged as one of the
fundamental experimental means in a broad range of application
fields, including protein biomarker studies [1–2], environmental
studies [3], etc. Yet it has also been extensively criticized as a
technique with poor repeatability and reproducibility [4]. In a
thoughtful paper on analysis of shotgun proteomics [5], Eckel-Passow
et al. discuss inherent difficulties in achieving good repeatability and
reproducibility even presuming technically superb mass spectrome-
try; and they explain the consequent challenges for statistical analysis
of shotgun proteomics data. For Multiple Reaction Monitoring
(MRM) measurements,the issuesaresomewhatdifferentandprovide
the opportunity to utilize the logic of [statistical] variance components
analysis to distinguish among sources of variability that can impair
both reliability and reproducibility.
In order to address the issues of reliability, reproducibility,
precision and instrument capability at multiple levels (within
laboratory, between laboratory, instrument-to-instrument, sample-
to-sample, limits of dectection (LoD) and quantitation (LoQ)), a
large-scale multi-site study was conducted to quantify MRM
measurements of a standarized mix of proteins in human plasma
[6]. The data analysis reported by Addona et al. [6] was done at a
micro level: linear regression models were fitted for individual
peptide groups measured at each site. Coefficients of variation (CV)
were then computed and reported for the linear response, percent
recovery, limites of dectection (LoD) and quantitation (LoQ).
The present paper addresses these same issues for MRM, using
the publically available data from the interlab study [6] as
illustration. Specifically, a variance components analysis of both
spiked-in control and test sample data partitions the variation in
peptide measurements into components that are attributable to the
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sub-studies. The analysis of the control data (heavy/isotopic
peptides) establishes the experiment’s reliability and reproducibil-
ity by the consistency of results. The analysis of test samples then
eliminates variation due to extraneous sources from the calculation
of the calibration curve and the precision estimates for that curve.
Mixed effects models are powerful and flexible tools for this
purpose [7]; so these are forumulated here as the basis for an in-
depth analysis of the variance components in the study. The
discussion of the rationale behind the specific choices of fixed vs.
random effects is provided in the Methods section.
This paper may be read in two ways, depending on the interests
of the reader. First, it may be read as a report of detailed results of
the interlab experiments [6]. Second, it may be read as a case study
or tutorial in the use of variance components analysis for MRM
calibration experiments.In the Methods section, the organization of
the statistical analysis is laid out stepwise to give an overview of the
analysis process that is subsequently presented in detail.
Methods
1) The study
Addona et al. [6] conducted their multi-lab experiment(8 sites)
using the technology of Multiple Reaction Monitoring (MRM)
coupled with stable isotope dilution mass spectrometry (SID-MS)
for the measurement of seven target proteins (11 unlabeled
signature peptides, i.e., 11 peptide groups) spiked into human
plasma. All the sites used the same protein mixture and spike-ins,
and followed the same standard operating procedure (SOP, refer
to Supplementary Document in [6]). Seven of them used 4000
QTRAP mass spectrometers. The eighth site used a different type
of mass spectrometer (ThermoFisher Quantum Ultra triple
quadrupole), which was excluded from our analysis.
The study comprised three sub-studies: Studies I, II and III, as
shown in the overall study design diagram in Figure 1. Study I was
conducted under the most controlled conditions, whereas Study
III was closest to a real experiment where almost all sources of
variations were involved. They were designed so that study
complexity as well as experimental variations increased from
Study I to Study III. In Study I, the light (
12C) and heavy (isotopic)
peptides were spiked into the digested human plasma. In Study II,
the digested proteins were spiked into the digested human plasma.
In Study III, the mixture of intact proteins and human plasma was
digested followed by mixing with the isotopic peptide groups.
Study III had three process/technical replicates. The light peptide
groups were measured over 9 different concentration levels,
whereas the heavy/isotopic peptide groups were at the same
concentration throughout to serve as an internal standard. For
each peptide group, three transitions were monitored; and for each
transition, four replicates were acquired. Therefore, excluding the
nested factor of transitions, each sub-study was a full factorial
design [8] for the remaining factors: studies (3), sites (7), and
peptides (11). What’s shown in each pair of parenthesis is the
number of levels for each factor.
2) Template for the Analysis
Figure 2 illustrates a generalflowchart of the variance component
analysis procedure. The first step is determination of the data
attributes including the scaling of the dependent variable(s) and the
identification of potential contributing factors or covariates, both as
part of the experimental design and as recorded ancillary variables.
With regard to the dependent variable, the goal of this step is to
understand whether or in what scale linearity is present (or not), and
whether the variance is homogeneous across the range of the
observations. For the factors and covariates, the goal is to determine
whether the model needs to apply exclusively to the specific
individuals/settings for each factor (‘‘fixed effects’’) or whether the
model is intended to generalize beyond these (‘‘random effects’’).
Discrete covariates are often treated as factors; for continuous
covariates the question is whether these are measured with only
negligible error, as is taken to be the case here.
The second step is to write down an initial model that includes
the putative factors and that represents their interrelationsships.
An interrelationship can be the interaction between two or more
factors (e.g., the differences between results for two sites are not
comparable for different peptides - hence site *peptide interaction
effect). Or, one factor may be nested in another, for example when
individual sites have different baselines from which each calculates
its own variance. Multi-site experiments typically exhibit both
kinds of interrelationships.
Now the model can be fitted (i.e., calculate the estimated
parameter/effect values) and tested. Testing has two aspects.
Verification that the model fits the data includes identifying
outliers, identifying heterogeneity of variance across the range of
observations, checking the residuals to look for patterns that
should be explained. Then, testing the parameter/effect estimates
for statistical significant follows.
The third step is to revise the model to omit factors, interactions
and covariates that do not contribute systematically to the value of the
dependent variable. Variances need to be recomputed at this point
(omitting any extreme outliers); residuals need to be reexamined for
definable patterns; and especially if the model is complicated, the
significant terms can be investigated further individually using
statistical tests. This step is important because, for example, a
‘‘significant interaction’’ between two factors might either occur
throughout the experiment or simply occur in just one or two
particular cases without being present otherwise (e.g., a difficult-to-
m e a s u r ep e p t i d em i g h tb ev e r yp o o r l ym e a s u r e da tj u s to n es i t ew h i l e
throughout the restof the experiment all the sitesare quite consistent).
It should be pointed out that this process may be iterative.
Especially removal of experimental outliers often increases the
resolution for the model-fitting so that trends or other patterns in
the residuals become evident, requiring additional revision to the
model itself and certainly to the variance (e.g., denominator of F-
test, also the degrees of freedom) used in statistical testing for
significance. Finally, the checking process culminates in validation
of the assumptions implicit in the analysis computations.
The final step will be model finalization. At this step, the
variance components of random effects as well as estimates of fixed
effects are computed.
The supplement contains additional tables, graphs of residuals
and influence analysis to confirm model adequacy and other
information which are too extensive to include in the text or that is
confirmatory rather than revelatory.
For this study, the analysis process takes place twice in
anticipation of potentially important effects of factors/covariates
in the data for the analyte, with the contrary expectation for the
spike-in control since the control monitors only the experiment
conditions and its conduct.
3) The data
Intensity was recorded as (peak) Area for each observation
(indexed by sub-study, transition, light or heavy peptide, technical
replicate) at each site. The first decision in the variance
components analysis is the determination of the appropriate scale
of measurement. The plot of Area vs. Concentration in Figure 3
for the light peptide group of one typical peptide bi0161 (PSA-
IVG) shows that for Area the variance increases with increasing
Variance Component Analysis
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that the analyses that follow are not disproportionately driven by
values at one end of the range of Areas seen in the study. At the
same time, like dilution and many calibration experiments, the
concentrations are approximately equally spaced in a log scale.
Transforming concentration to the log scale also serves to help
equalize the influence of the concentrations at the ends and the
middle of the concentration range.
The effectiveness of the log transformation is illustrated in
Figure 4 by the linear relationship of the mean logArea vs.
logConcentration for the light peptide (PSA-IVG) and for its
isotopic/heavy counterpart. Also, stabilizing the variance and
controlling the influence of individual concentrations (especially at
the extremes) satisfies the requirements for correct variance
component analysis (and other analysis of variance methodology).
Therefore all the analyses hereafter will be in the logarithm scale.
Note that since the log transformation of blank concentration does
not exist, in our analysis, we used only the spiked-in concentration
levels, which are greater than zero.
A consequence of the log-log transformation is the linearity of
the calibration curves for each of the three sub-studies. From
Figure 4 the study-to-study differences show clearly as increments
in logArea, with slight differences in slope for the internal controls
(heavy peptides) or for the calibration test samples (light peptides).
Figure 1. Illustration of three sub-studies in the study. Note that the complexity was increased from Study I to Study II to Study III.
doi:10.1371/journal.pone.0014590.g001
Figure 2.Sketch flowchart of variance component analysis procedure.
doi:10.1371/journal.pone.0014590.g002
Variance Component Analysis
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The purpose of a variance components analysis of a calibration
experiment is to determine, as precisely as the data allow, the
calibration curve, i.e., the function that relates the measurement
(logArea) to the stimulus (logConcentration), after eliminating the
contributions of other factors and/or covariates to the data values.
This is accomplished by decomposing the simplistic variance
calculations into parts associated with each of the input factors or
covariates and with any important interactions among these. This
separation extracts the ascribable variation due to sources other
than the relationship of primary interest, leaving only this primary
relationship to be estimated together with its remaining variation
and hence the goodness of fit for this primary relationship.
For this calibration experiment the relationship of primary
interest is logArea as a function of logConcentration; other input
factors include the specific sub-study, site or laboratory, peptide
group and transition nested within peptide group. Allowing for
potential site-to-site differences in moving from one sub-study to the
Figure 3. Plot of Area under the peak vs. Concentration for bi0161 (PSA-IVG) acquired in Study I at Site 19, showing the correlation
of mean and variance and therefore suggesting log transformation of the data.
doi:10.1371/journal.pone.0014590.g003
Figure 4. Mean values of logArea vs. logConcentration of PSA-IVG (A, triangles) and its isotope (I, circles) in Study I (1, black), Study
II (2, red) and Study III (3, blue). In the log-log scale, the light peptides’ relationship to concentration is linear. The heavy peptides (isotopes)
served as internal standard with constant concentration as shown.
doi:10.1371/journal.pone.0014590.g004
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potential site-to-site differences in peptide measurement, transition-
to-transition variability, etc. And, of course, the model includes the
‘‘residual error’’ that cannot be assigned to any of these sources.
Because the complexity of the MRM study increased from
Study I to Study III, the variance was also expected to increase.
Each study (i.e., sub-studies) is considered to be a fixed effect. Other
effects are considered to be random, so that the model is mixed
(and all interactions involving one or more random effects are per
force random).
In order to estimate the variance components, it was assumed
that the area measurements after logarithm transform (denoted by
logArea) followed a multivariate normal distribution. Of course, to
analyze the data for the internal standard, there is no
logConcentration term in the model because the spike-in was at
constant concentration across all samples. So the mixed effects
ANOVA model for the heavy peptides had the following form
(Model 1):
logAreaIS~D
zc(D)zszpzt(p)zD  szD  pzs  p
zD  t(p)zs  t(p)zD  s  pzD  s  t(p)ze,
where study (D) is a fixed effect representing individual sub-studies;
site (s) and peptide group (p) are random main effects with variances of
ss
2 and sp
2 respectively; technical_replicate nested within study (c(D))
and transition nested within peptide group (t(p)) are random nested
effects with variance of sc(D)
2 and st(p)
2 respectively; additional
random effects include the two-way interactions (study*site
,sDs
2., study*peptide ,sDp
2., and site*peptide ,ssp
2.), three
three-way interactions (study*transition(peptide) ,sDt(p)
2., site*transi-
tion(peptide) ,sst(p)
2., and study*site*peptide,sDsp
2.), and one four-
way interactions (study*site*transition(peptide) ,sDst(p)
2.); e denotes
the residual error term assuming e to be iid (independent and
identical distribution) Gaussian with mean 0 and variance sr
2.
In thismodel,withsite asa randomeffect,one consequenceisthat
there is a common correlation among all observations within a site.
When declaring peptide group as a random effect, there is also a
common correlation among all observations for the same peptide
group. Likewise, the higherorder interaction random effects assume
common correlations between all observations that had the same
level of the corresponding combination of factors. A multivariate
model with this covariance structure provides a reasonably good fit
to logAreadata.Theunknown parameters inModel 1 areestimated
via restricted/residual maximum likelihood (REML) algorithm [9].
Wald Z-tests [10] are used to test the significance of the covariance.
For the light peptides, in addition to the four class-type factors
(study, site, peptide group and transition nested within peptide group)
considered in Model 1, continuous variable of primary interest,
i.e., the concentration level (log scale, denoted by logConc) is added to
the model. As shown in Figure 4, the relationship between the Area
and the Concentration is linear in log scale, so for the light peptides
(i.e., the analytes, A) alone, the full model is (Model 2):
logAreaA~logConczDzD  logConc
zc(D)zszpzt(p)zD  szD  pzs  p
zD  t(p)zs  t(p)zD  s  pzD  s  t(p)ze,
where logConc, study (D) and the interaction between study and
logConc are fixed effects; again, site (s) and peptide group (p) are
random main effects; technical replicate nested within study (c(D)) and
transition nested within peptide group (t(p)) are random nested effects; and
additional random effects are the same as in Model 1; e, the residual
error, is assumed to be iid Gaussian with mean 0 and variance sr
2.
Including the study (D) term in the model allows the intercept of the
linear regressions to vary from sub-study to sub-study. By including
the interaction term between study and logConc, the slopes of the
linear regression also vary with respect to the sub-studies.
In this multi-site study, the measurement of heavy peptides also
enabled an alternative analytic approach: to model the area ratio
of the light peptides (A) to the correponding isotopic counterparts
(IS). In the log scale, this is equivalent to subtracting the logArea
values of the heavy peptides from those of the light peptides. The
model takes the following form (Model 3):
log(AreaRatio)~logAreaA{logAreaIS
~logConczDzD  logConc
zc(D)zszpzt(p)zD  szD  pzs  p
zD t(p)zs t(p)zD s  pzD  s  t(p)zelr,
note that elr is the residual error for measurements of the log ratio.
Other notations follow those in Model 2.
Models 1, 2 and 3 all assume the homogeneity of variance
among peptide groups, which has a common form as follows:
dependent term~fixed effects
zc(D)zszpzt(p)zD  szD  pzs  p
zD  t(p)zs  t(p)zD  s  pzD  s  t(p)ze:
To allow for heterogeneity of variance among peptide groups,
the following simplified mixed effects model formula is considered
(Models 4–6):
dependent term~fixed effects
zc(D)zszpzt(p)
zD  pzD  s  pze,
where in the SAS implementation the group effect is specified to
be peptides. The covariance matrix is thus block diagonal with
blocks corresponding to the individual levels of factors containing
peptide groups. Other notations are as before.
Similarly, to allow for heterogeneity of variance among sites, the
following simplified mixed effects model formula is considered
(Models 7–9):
dependent term~fixed effects
zc(D)zszpzt(p)zD  szs  pzD  s  pze,
where in the SAS implementation the group effect is specified to
be sites. The covariance matrix is thus block diagonal with blocks
corresponding to the individual levels of factors containing site.
Other notations are as before.
The treatments of factors in these models are summarized in the
Figure S1.
Results
The significant level in our study is set at 0.05. Figure 5
summarizes the results (individual variance components and
Variance Component Analysis
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between Model 1 (for heavy peptides) and Model 2 (for light
peptides) shows that the variability estimates are generally quite
consistent for the random effects. For example, the residual errors
for the two analyses were comparable (0.7511 vs. 0.7545). The
variance components of site are also comparable (0.6446 vs.
0.6983). The variance component of peptide is smaller in Model 2.
However, for the interaction term of study*peptide, Model 2 has
larger variance component (0.82 times of the residual variance,
significantly greater than 0 based on Wald test in Table S2) than
Model 1 (0.06 times of the residual variance, significantly greater
than 0 based on Wald test in Table S1). The variance components
of transition nested with peptide are significantly greater than 0.
Models 2 and 3 are both for the analysis of the light peptides.
They differ in the dependent variables: Model 2 considers the
logArea of the light peptides alone, whereas Model 3 considers the
log area ratio of light peptides vs. heavy peptides. Comparison of
the variance components of these two models (Figure 5) shows that
the residual error of Model 3 is smaller than that of Model 2 and
the majority of the factors have diminished variance components.
In Model 3, the study*peptide term is the dominant variance
component (both large and significant), whose variance relative to
residual variance is 1.51. It suggests that the peptide groups may
play an important role in the variance component analysis of the
study. This motivates the new models that allow for different
variances for different peptide groups.
Models 4 to 6 allow for the heterogeneity of variance among
peptide groups for the heavy peptides, light peptides and the area
ratio, respectively. Their variance components results are shown in
Figure 6 (a) to (c). In Figure 6 (a), there is one predominantly high
peptide component corresponding to Peptide ni0001 (14.4118, which
is 18.55 times of the residual variance). In Figure 6 (b), the same
component of Peptide ni0001 remains high (9.4748, which is 11.30
times of the residual variance). In addition, the ‘study*peptide’
component of Peptide bi0170 is also high (4.82 times of the residual
variance). In Figure 6 (c) The peptide component corresponding to
Peptide ni0001 is diminished, but its ‘study*peptide’ component has
increased. Moreover, the ‘study*peptide’ component of Peptide
bi0170 remains high. Consistently, on Figure S4 of restricted
likelihood distance plot showed that deleting peptide bi0170 resulted
in the dramatically increased restricted likelihood distance from
others. It seems that Peptides ni0001and bi0170 are the major
contributors to the large variability across peptides either directly or
through interaction with study or both. Therefore Model 3 and
Model 6 are also refitted without these two outlier peptides. The
corresponding results are shown in Figure 5 and Figure 6 (d). As
expected, excluding the pair of more variable peptides results in the
reduction in the variance attributable to the residualsand the site effect.
In addition, three more models (Models 7 to 9) are considered for the
heterogeneity of variance among sites. Their variance components
results are shown in Figure 7 (a) to (c). The result corresponding to
Model 9 without the two outlier peptides are shown in Figure 7 (d).
The ANOVA table of fixed effects of Model 3 excluding Peptides
ni0001 and bi0170 is given in Table 1. Both the intercepts and
slopesofthelinearregressionsdiffersignificantly amongsub-studies.
Further analysis using Student t-test provides for each sub-study the
estimates of fixed effects, which are tabulated in Table 2. What’s
reported in the table are the raw p-values using Study III as
reference. The three studies has decreased slope from Study I to
Study II to Study III. The intercept of Study I is significantly higher
from Study III, whereas the intercept of Study II is not significantly
different from Study III.
The covariance parameter estimates and the Wald Z-test of
heavy peptides using Models 1–3 are displayed in Tables S1, S2,
S3, respectively. The null hypothesis of the Wald Z-test is the
hypothesis of null contribution, i.e., the variance component
equals to zero. So the null hypothesis is rejected for small p-values.
That is, the variance of a specific component was significantly
Figure 5. Variance components of Model 1 for heavy peptide data, of Model 2 for light peptide data alone, and of Model 3 for Area
Ratio data using whole set and using the subset excluding two peptides ni0001 and bi0170. The error bars represent the standard errors.
doi:10.1371/journal.pone.0014590.g005
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Models 1 to 3 are significantly greater than zero. Note that the p-
values in our paper were just reported based on the ANOVA
analysis, and no model selection or variable selection was
attempted based on p-values.
Discussion
Two objectives motivate this paper: to further illuminate the
results of the inter-lab study, and to demonstrate the capabilities
and value of mixed effects models for analyzing proteomics data.
Figure S1 provides a context for the discussion by chronicling
the information elucidated at each step of the variance
components analysis for the dataset in the Addona et al. paper.
Mixed effects models are a methodology of choice because they can
incorporate complex experimental designs with multiple factors into
the analysis; and hence are applicable to multi-factor and multi-site
experiments. These models separate the variability due to the different
experimental factors and to the residual noise. Moreover, they can
model the higher-order interaction terms in a directly interpretable
way, which other approaches such as Principle Component Analysis
(PCA) cannot. As occurred in the example here, the impact of a factor
may appear through an interaction even more prominently than
through its direct effect. Through mixed effects modelling, the
correlation structure of the data can be explicitly examined by
researchers. The flexibility of mixed effects models combined with
their inferential power make them a unique and very valuable tool in
mass spectrometry-based proteomics research, as is demonstrated
through the analysis of this multi-site dataset.
Several characteristics of the experimental design in this study
may cause problems or result in faulty interpretation for other
analysis tools while variance components analysis via mixed effects
models can even take advantage of the design to provide
additional information to the researchers. The multilab study
was designed with increasing complexicity from Study I to Study
III. Therefore in the mixed effects models the study factor is treated
as a fixed effect. For the heavy peptides, four additional class-type
factors (technical replicates nested within study, sites, peptides and transitions
nested within each peptide) are modeled as random effects, and higher
order interaction terms are also included. Modelling these random
effects allows for the correlation among all observations that share
the same level of each factor. Additionally, by considering a factor
(e.g, sites) as a random effect, the inference can be applied to an
entire population (e.g., experimental sites in general) rather than
being restricted to only the particular subsets of the data (e.g., the
seven sites). It should be noted here that the purpose of the
Addona et al. study was to establish broad reproducibility that
would be relevant to high quality labs in general. If the goal had
been different, for example, to characterize or to calibrate the
seven sites, as might be done for an expanded future series of
studies, then the sites would have been considered fixed. Of
course, the appropriate analysis with sites considered fixed, would
give the same variance estimates for the remaining terms. Only
site*study would be a fixed interaction effect rather than a random
interaction effect (the interaction of site with the other random
factors would lead to random interactions).
A second aspect of the study design is that the signals of both the
analytes (i.e.,light peptides) and their isotopic counterparts (i.e., heavy
peptides) are recorded for all experimental units in this study, and the
heavy peptides serve as internal standard of the experiment. Thus the
variance components analysis for the internal standard can serve to
identify sources of variation that are part of the experimental
procedures, and simultaneously to provide baseline evidence on the
q u a l i t yo ft h ee x p e r i m e n t .E s s e n t i a l l y ,t h ev a r i a n c ec o m p o n e n t s
analysis for the analytes distinguishes the pervasive sources of
experimental variation from variation that is specific to the test
material. In the cases of both analyte and heavy isotope, the variance
components analysisproceeds through a similar series of steps. Firstly,
terms in the model (effects) are identified that contribute the largest
components to the variance (or equivalently, extract the most overall
variation leaving the least residual variance). Next, if those effects can
be subdivided, then the most significant ones (greatest contributors)
are identified in order to focus special attention on the possibilities
that either the significance of the result depends on a single specific
sub-component or that an outlier observation distorts the importance
of one term in the model. Discovery of an outlier or of an observation
with excessive influence may then lead to deletion of observation(s)
and refitting the model, to be followed by verification of the model’s
goodness of fit to the data via examination of residuals and
consideration of influential observations, etc.
The separation of variances arising from different experimental
factors and from the residual noise is achieved as follows. From the
successfully fitted model, the contributions to variation are
quantified in terms of the reduction in total variation (R-squared)
that is assignable to each effect; interactions are represented in
terms of the covariances between each pair of effects. Then F-tests
are used for significance testing; or in the case of single degree-of-
freedom contrasts their counterpart t-tests are equivalent.
For the control data based on Model 1, the failure to find
significance for sites or for technical replicates is indicative of a well-
controlled experiment. In the case of the multilab study, this is
precisely what happens, as is evident in Figure 5. However, the
variance components related to the factors of peptides and transition
nested within peptide are much larger than other higher-order
interaction terms when compared to the residuals. Moreover, the
significance for transitions nested within peptide effects is high, which is
quite unexpected. Model 4 allows for the variances among
different peptides to be different, and its corresponding result in
Figure 6 (a) for the control data shows that the high variability of
peptides was primarily driven by a single very high component
corresponding to Peptide ni0001. Model 7 allows for the
heterogeneity of variance among different sites. Its result in
Figure 7 (a) for the control data shows that Site 19 has higher ‘site’
variance component than the other sites.
For the analysis of light peptides alone, the relationship of the
peak area values with the concentration levels is linear in the log-
log scale. To allow for the differences that could arise from
changing SOP, the multiple factor mixed model to fit the compiled
data from several sub-studies, allows the intercept and the slope to
change from one sub-study to the next. The variance components
analysis of this model gives similar results to the one in Model 1 for
heavy peptides. For example, even though the ‘peptide’ component
is smaller for the analysis of light peptides alone, it is offseted by
larger ‘study*peptide’ component.So the overal peptide effect remain
similar. By looking into the hetergeneous peptide components
model of light peptides (Model 5), Peptide ni0001 still gives a much
higher ‘peptide’ component than others. Moreover, Peptide bi0170
comprises a major ‘study*site’ variance component. From the
heterogeneous site components model of light peptides (Model 8), it
seems that Site 19 still has higher ‘site’ variance component than
Figure 6. Variance components of models allowing for the heterogeneity of variance among peptide groups. Panels (a)–(c) correspond
to Models 4 to 6 respectively, and Panel (d) corresponds to Model 6 without Peptides ni0001 and bi0170.
doi:10.1371/journal.pone.0014590.g006
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the decreased ‘peptide’ components are offseted by the increased
‘study*site*peptide’ components.
Utilizing the heavy peptide signals as an internal standard (by
calculating the peak area ratio, or in log scale, subtracting the logs
of heavy peptide measurements), removes this source of experi-
mental variability. Thus as shown in Figure 5, the remaining
variability of the light peptide measurements truly due to the
majority of factors is seen to be effectively reduced with the
exception of ‘study*peptide’ component. By checking the heteroge-
neous peptide components model of the logAreaRatio (Model 6),
the high variability of ‘study*peptide’ is due to Peptides ni0001 and
bi0170. The result based on the heterogeneous site components
model of the logAreaRatio (Model 9) is shown in Figure 7 (c).
Comparing it against Figure 7 (a) and (b), it’s impressive to see that
the majority of the variance components reduce greatly, including
those for Site 19. The only remaining high components are those
‘study*site*peptide’ interactions. This demonstrates the effectiveness
of using heavy peptide signals as an internal standard.
In summary, after considering the Area Ratio of light peptides
vs. heavy peptides, the variability of measurements related to
factors involving peptides persist with respect to the residuals. The
question then arises whether there is general variability among
peptide groups or whether one or a few peptides exhibit
dramatically different behavior from the rest of the groups. Based
on the evidence so far, the variability corresponding to light
peptide groups ni0001 and bi0170 is much higher than the other
peptides. They correspond to the peptides of CRP-YEV and
MBP-YLA, respectively. Addona et al. [6] also found CRP-YEV
(ni0001) to be problematic and excluded it from analysis. This
concords with the finding here that its variance component is
much higher than those of other peptides when considering either
light (Figure 6 (a)) or heavy peptides alone (Figure 6 (b)). Using
area ratio as the variable of interest actually greatly diminishes the
variability for this peptide, as is shown in Figure 6 (c) where the
plots are in smaller scale than in Figure 6 (a) and (b). Yet Figure 6
(c) shows that both peptides ni0001 and bi0170 have higher
variance components corresponding to the interaction term of
study* peptide. Therefore, they are considered peptide outliers.
Following removal of the two peptide outliers, the variance
components analysis yields no significant random effects factors with
respect to the residuals (Figure 5). The result based on the
heterogeneous site components model of the logAreaRatio (Model
9) without the outlier peptides is shown in Figure 7 (d). Comparing it
to Figure 7 (c), the previously high ‘study*site*peptide’v a r i a n c e
components are reduced. While all other components remain very
small, meaning that the two outlier peptides contribute essentially all
theexcessvariationforthepeptidefactor.Inaddition,thecomponents
are quite consistent across different sites except that Site 54 has
higher ‘tech_replicate(study)’ component than others. The restricted
likelihooddistancevs.deletedsiteplotusingModel3withoutthetwo
outlier peptides ni0001 and bi0170 is shown in Figure S5, also
pointing out that Site 54 does in fact differ from other sites.
The ANOVA table in Table 1 shows that the intercepts and
slopes of the calibration curves are different among sub-studies;
and Table 2 provides more information about the fixed effect
estimates for each sub-study. Slopes of logArea vs. log Concen-
tration plots represent the sensitivity of the proteomics procedure.
Table 2 shows that the slopes decrease from Study I to Study II to
Study III, as expected, because the complicated digestion process
would likely impair the sensitivity of the proteomics procedure.
As is shown above, mixed effects modeling provides powerful
inference to this dataset. Yet, care needs to be taken to use it
properly, since it has some basic assumptions, which are usually
checked in the first step of the variance component analysis
(Figure 2). One assumption is that variances are stablized for a
range of predictive variables. In the multilab dataset, the raw data
of areas under the peaks exhibits correlation between means and
variances at different peptide concentrations. Therefore the raw
data are transformed into log scale to stablize the variance over a
wide range of concentration levels. The residual plots for Model 2
and Model 3 are shown in Figures S2 and S3, respectively.
Model selection is an important aspect of using mixed effects
models properly. Depending on the data, either linear or
generalized linear models can be used. The multilab dataset, as
shown in Figure 4, exhibits a general linearity between logArea
and log Concentration. A companion study is underway to study
the individual linearity of the calibration curves.
The data considered here came from the seven sites that used
the same mass spectrometry platform. Mixed effects modeling
methodology can be easily expanded to apply to ensemble data
from different platforms. Of course models become more complex
with added terms and interactions to investiagate the contributions
of various platforms to differences in results. A difficult problem
can arise in this comtext when platforms are not replicated at
different sites or when the experiment design becomes unbalanced
with respect to platform and any other feature (e.g., SOP). In such
cases, it can be impossible to distinguish the effect of the individual
site from the effect of the platform; it does become impossible
when the site used it uniquely.
In conclusion, mixed effects modeling is a valuable tool in mass
spectrometry-based proteomics research. The primary purpose of
these studies conducted by the multilab team is to test the
consistency in the Multiple Reaction Monitoring (MRM) mea-
surements of proteins in human plasma across multiple sites.
Results from mixed effects modeling show that the variance
attributable to the factors involving sites is very small with respect
to the residuals when the log area ratio of the light peptides to the
Figure 7. Variance components of models allowing for the heterogeneity of variance among sites. Panels (a)–(c) correspond to Models 7
to 9 respectively, and Panel (d) corresponds to Model 9 without Peptides ni0001 and bi0170.
doi:10.1371/journal.pone.0014590.g007
Table 1. F-test of fixed effects in Model 3 for area ratio excluding Peptides ni0001 and bi0170.
Effect Numerator Degrees of Freedom Denominator Degrees of Freedom F Value Pr . F
logConc 1 3.30E+04 2.48E+05 ,.0001
study 2 8.92 4.62 0.042
logConc*study 2 3.30E+04 2.59E+02 ,.0001
doi:10.1371/journal.pone.0014590.t001
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measurements are consistent across the labs given that they follow
the same standard operating procedures. In addition, the heavy
peptide can be used as an effective internal standard for reducing
apparent inter-site variability.
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